MSS Clinical Trial
Official title:
QL1101A,a Biosimilar of Bevacizumab,in Combination With JS001,a Anti-pd-1 Antibody in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer: a Single-arm,Open-Label, Prospective, Single-center Study
This is a single-arm,open-label, prospective, single-center Study of QL1101 and JS001 in
patients with pMMR/MSS refractory metastatic colorectal cancer.
QL1101 is a biosimilar of bevacizumab (Avastin) produced and provided by Qilu Pharmaceutical
Co., Ltd., which has been marketed in China.It's a humanized monoclonal IgG1 antibody
prepared by recombinant DNA technology. By binding to human vascular endothelial growth
factor (VEGF), it inhibits the binding of VEGF to its receptor, blocks the signal
transduction pathway of angiogenesis, and inhibits tumor cell growth. Be produced and
provided by Shanghai Junshi Bioscience Co., Ltd. ,JS001(Tripleitriumab) is the first
China-developed humanized monoclonal antibody against programmed death 1 (PD-1) approved for
marketing in China.
Antiangiogenic drugs combined with PD-1 monoclonal antibodies may reverse the insensitivity
of pMMR/MSS refractory colorectal cancer to PD-1 inhibitors.
The primary objective of this study is to investigate the safety and efficacy of the subjects
who given the combination therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04659382 -
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT03271047 -
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
|
Phase 2 | |
| Recruiting |
NCT05815303 -
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06321081 -
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
|
Phase 2 | |
| Active, not recruiting |
NCT05733611 -
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
|
Phase 2 | |
| Not yet recruiting |
NCT06415851 -
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
|
Phase 2 | |
| Recruiting |
NCT04483219 -
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
|
Phase 2 | |
| Active, not recruiting |
NCT04046445 -
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
|
Phase 1 | |
| Recruiting |
NCT04030260 -
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05877573 -
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
|
N/A | |
| Recruiting |
NCT06199232 -
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
|
N/A | |
| Recruiting |
NCT05731726 -
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05933980 -
Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT03274804 -
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
|
Phase 1 |